Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
|Articles|December 13, 2004
2005: WHAT'S ON THE HORIZON?
As calendar years go, 2004 has not been a tame one by any standard, starting out with utter confusion over the Medicare discount cards and ending with President Bush beating John Kerry in a close Presidential race.
Advertisement
Advertisement
Related to this article
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
To guide public health and vaccination strategies, researchers assessed a variety of factors regarding community-acquired pneumonia and its causes.
Highlighting the clinical impact of the pharmacy profession, we caught up with pharmacists of various types to get their perspectives on the evolution of pharmacy.
A newly erected Women’s Health Division within NIH will work in tandem with the Office of Research on Women’s Health.
Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.
Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Advertisement
Advertisement
Trending on Drug Topics
1
EloraTZP Shows Greater Weight Loss, A1C Reduction Than Tirzepatide
2
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
3
CagriSema Reduces Weight in Women Across Menopause Stages, HT Use
4
White House Declares Increased Focus on Women’s Health in US
5